Our Board ensures that all our projects are conducted with utmost integrity, keeping in mind the interests of our stakeholders. Board Members also set and guide Hilleman Laboratories strategic direction providing counsel and oversight to meet goals and key milestones.
Our eminent Board members are individuals having profound expertise in the sphere of vaccine development and public health.
Dr. Gerd Zettlmeissl
(Chairman, Hilleman Laboratories)
Dr. Gerd Zettlmeissl is the former Chief Executive Officer of the Austria-based biotechnology company Intercell AG and is an accomplished vaccine expert and biopharmaceutical business executive. Gerd Zettlmeissl has more than 25 years of scientific and leadership experience in the biopharmaceutical industry. While at Intercell AG from 2001 to 2011, he built the company from a private start up company to a publicly listed international organization with more than 400 employees. As CEO, he secured regulatory approval and led the launch of an improved Japanese Encephalitis vaccine, and oversaw efforts to build and advance a broad based development portfolio of vaccines. Prior to joining Intercell, Gerd Zettlmeissl held senior management roles at Chiron Corp. and Behringwerke AG. In 2010, he was named Vaccine Biotech CEO of the Year at the World Vaccine Congress.
He currently serves on various Supervisory Boards. Inter alia he is Chairman of the Supervisory Board of GlycoVaxyn, a vaccine biotech company in Switzerland, and a member of the Board of Aeras, a non-profit organization developing tuberculosis vaccines.
Julie Louise Gerberding, M.D., M.P.H.
Director - Hilleman Laboratories
Dr. Julie Gerberding is Executive Vice President and Chief Patient Officer, Strategic Communications, Global Public Policy, and Population Health at Merck & Co., Inc., where she also has responsibility for the Merck for Mothers program and the Merck Foundation. As Chief Patient Officer, Dr. Gerberding leads efforts to engage with patients and patient organizations to bring their perspectives into Merck and MSD to help inform company decisions and represents Merck globally on patient-related matters. In addition, she is building new initiatives designed to accelerate Merck’s ability to contribute to improved population health, a measure increasingly valued by consumers, health organizations, and communities.
As a world-renowned infectious disease and public health expert, Dr. Gerberding is a leader well-versed in and passionate about acting with purpose and urgency to meet patient needs. She joined Merck in January 2010 as president of Merck Vaccines and, during her leadership of that business, helped make the company’s vaccines increasingly more available and affordable to people in emerging markets and some of the most resource-limited countries in the world. Dr. Gerberding also helped lead the successful launch in India of the MSD Wellcome Trust Hilleman Laboratories, a not-for-profit joint venture for vaccine development. In 1998, she left her tenured academic faculty appointment at the University of California, San Francisco, to lead the U.S. Centers for Disease Control and Prevention (CDC) Division of Healthcare Quality Promotion and then served as the CDC Director from 2002 to 2009.
As director, Dr. Gerberding led the CDC through more than 40 emergency responses to public health crises, including anthrax bioterrorism, SARS, and natural disasters. She also advised governments around the world on urgent issues such as pandemic preparedness, AIDS, antimicrobial resistance, tobacco, and cancer. At the University of California, San Francisco (UCSF), Dr. Gerberding directed the Prevention Epicenter, a multidisciplinary research, training, and clinical service program that focused on the prevention of infections in patients and their healthcare providers.
Dr. Gerberding received her undergraduate and M.D. degrees from Case Western Reserve University (CWRU). She completed her internship and residency in Internal Medicine and fellowship in Clinical Pharmacology and Infectious Diseases at the University of California, San Francisco (UCSF), where she is currently an Adjunct Associate Clinical Professor of Medicine in Infectious Diseases. Dr. Gerberding received a Masters of Public Health at the University of California, Berkeley. She is a member of the Institute of Medicine and a fellow of the Infectious Diseases Society of America and the American College of Physicians, and is board certified in Internal Medicine and Infectious Diseases.
Dr. Gerberding currently serves on the Boards of Cerner Corporation, CWRU, MSD Wellcome Trust Hilleman Laboratories, and the BIO Executive Committee. Dr. Gerberding has received more than 50 awards and honors, including the United States Department of Health and Human Services (DHHS) Distinguished Service Award for her leadership in responses to anthrax bioterrorism and the September 11, 2001 attacks. She was named to Forbes Magazine's 100 Most Powerful Women in the World in 2005 through 2008 and to TIME Magazine's 100 Most Influential People in the World in 2004.
Prof. Gagandeep Kang
Director - Hilleman Laboratories
Professor Kang is currently Executive Director – THSTI, Faridabad and Head of the Wellcome Trust Research Laboratory at the Christian Medical College (CMC) in Vellore, India. Over the past two decades, she has built a research program that has conducted key studies to understand enteric infectious diseases in impoverished communities. Gagandeep’s research has demonstrated the high burden of rotavirus disease across India, the genetic diversity of viruses and the factors that affect transmission and disease in hospital and community settings. She has investigated the protection induced by natural infection in the largest birth cohort study on rotaviral infections in the world. Working in partnership with non-governmental organizations and the government, she has carried out phase I-III studies of rotaviral vaccines and provided laboratory support for vaccine development in India and for other developing countries. With the Indian Council for Medical Research and the World Health Organization, she has supported the establishment of networks of sentinel hospitals and laboratories that carry out surveillance for rotavirus disease in children and ancillary studies.
Professor Kang has built a strong inter-disciplinary research program that uses careful and detailed field epidemiology with molecular tools for characterization of infectious agents and host response to infection to understand and change factors that affect transmission, development and prevention of enteric infections and their sequelae. Observational, interventional and mechanistic studies on enteric infection and nutrition have demonstrated the complex relationships between gut function and physical and cognitive development. Based at an outstanding medical college, she has established a strong training program for students and young faculty in clinical translational medicine aiming to build a cadre of clinical researchers studying relevant problems in India. The large body of research conducted by her group has led to practical interventions to prevent diarrhoeal disease, and continues to lay the groundwork for further interventions in the form of treatment techniques and vaccines. Dr. Kang has published over 200 papers in national and international journals. She is an Associate Editor for PLoS Neglected Tropical Diseases and for Tropical Medicine and International Health, on the editorial board of Scientific Reports and is on several review committees for national and international research funding agencies.
She is a member of the WHO's Global Advisory Committee on Vaccine Safety and the Immunization and Vaccine Implementation Research Advisory Committee and chairs the Immunization Technical Advisory Group for the WHO’s South East Asian Region. She serves on the scientific advisory committee of national and international institutions, including the National Institute of Biomedical Genomics, the Translational Health Science Technology Institute and the International Vaccine Institute. She is an Independent Director of the Biotechnology Industry Research Assistance Council, a section 8 company established by the Government of India.
Director - Hilleman Laboratories
Sanat Chattopadhyay is Executive Vice President of Merck and President of the Merck Manufacturing Division, with responsibility for Merck’s worldwide manufacturing operations supporting global sales revenues of approximately 40 billion USD. Merck is known as MSD outside of the U.S. and Canada.
He and his leadership team oversee a network of manufacturing, commercialization and distribution sites that produce pharmaceutical, vaccine, biologic/therapeutic protein and animal health products. Approximately 20,000 full-time and part-time employees work in the network, which spans more than 20 countries.
Mr. Chattopadhyay serves as a member of Merck’s Executive Committee. He has a proven senior leadership track record of commercialization, manufacturing and supply chain excellence in therapeutic proteins, vaccines and pharmaceuticals for Hoechst, Aventis, Wyeth and Merck for more than 30 years.
Outside Merck, Mr. Chattopadhyay serves on the Board of Directors of Hilleman Laboratories, an equal joint-venture partnership formed between Merck and Wellcome Trust, a global charitable foundation dedicated to human and animal health. He is also a member of the Advisory Board of USA-India Chamber of Commerce.
Before joining Merck in November 2009, Mr. Chattopadhyay worked for Wyeth Pharmaceuticals as Senior Vice President, New Products & Process Development. A graduate Chemical Engineer and a post-graduate Industrial Engineer from India, he started his career with Hoechst Pharmaceuticals in 1983 and worked in many senior leadership assignments in 5 countries across 3 continents, rising to the level of Senior Vice President, Product Development & Supply at Aventis where he led global supply chain, including new product commercialization, technology and engineering.
In his current role, Mr. Chattopadhyay has successfully launched a new strategy for the manufacturing and supply organization, restructured into independent but interconnected business units based on technology platforms and further integrated supply planning and operations across the company.
Prof. Gordon Dougan
Director - Hilleman Laboratories
Professor Dougan is currently Head of Pathogen Research and a member of the Board of Management at The Wellcome Trust Sanger Institute (WTSI) in Cambridge, United Kingdom. He is also an Honorary Professor at Cambridge University and a Fellow of Wolfson College. Gordon’s personal research team studies enteric pathogens with a strong emphasis on basic pathogenic mechanisms and immunology and he contributes to the Mouse Genetic Programme running an infection screen in novel gene KO strains. Gordon has a particular interest in using genomics to study host/pathogens interactions, in particular using Salmonella enterica serovar Typhi, the cause of typhoid, as a model. He has extensive experience working both in industry and in academia. Before moving to the WTSI he was the Director of the Centre for Molecular Microbiology and Infection at the Imperial College London and a Professor of Physiological Biochemistry. There he was responsible for securing multi-million pound funding for a new building in Kensington and providing infrastructure for the science.
Throughout his career Gordon has served as a referee, advisor and consultant for numerous respected institutions, universities, boards, committees and other organizations. He was a Trustee of the International Vaccine Institute in Korea and has worked with other global agencies including WHO and GAVI. Gordon was elected a Fellow of the Academy of Medical Sciences in 2002. He is a member of EMBO and was elected Fellow of the Royal Society in 2012. He graduated with a degree and received his Ph.D. from the University of Sussex. Gordon conducted postdoctoral studies at the University of Washington (Seattle) in the laboratory of Stanley Falkow. He worked for over ten years in industry developing vaccines and novel drugs at an internationally renowned multinational company. Gordon has participated in early and late clinical studies on several vaccines; he is an expert in vaccinology/pathogenic mechanisms, specialising on the immunology of mucosal vaccines and molecular basis of infection. Gordon is currently Chair of the Novartis Vaccines & Diagnostics SAB and has spun out a number of companies. He has published over 400 research papers, edited several books and has sat on the editorial boards of a number of prestigious journals.
Michael T Nally
Director - Hilleman Laboratories
Mike Nally is President of Global Vaccines at MSD. MSD, with a $6 billion vaccines business, is a global leader providing a broad portfolio of pediatric, adolescent, and adult vaccines to the world. In his role, Mike aims to drive a dramatic increase in the reach and public health impact of vaccines, while delivering business growth.
Prior to this appointment, Mike led the company's business in Sweden and the UK, focusing on the development and implementation of innovative, customer-centered approaches that delivered improved business results and accelerated patient access to our medicines.
Mike holds a MBA from Harvard Business School, a degree in Accounting and Finance from the London School of Economics and a BA in Economics from Middlebury College.